Sanguine Biosciences – Accelerate precision translational medicine and cell & gene therapy development with biospecimens directly from patients – Distributed in the UK and Ireland by Caltag Medsystems
Sanguine Biosciences
Sanguine Biosciences strives to accelerate research and discovery by bridging the gap to obtaining biospecimens with a robust donor network. By directly engaging with donors, they can identify and collect the biospecimens necessary for advancing discovery.
Sanguine has supported translational, clinical, and cell & gene therapy research for 35 of the top 40 global pharmaceutical and biotechnology companies, shortening timelines and validating early-stage results to increase confidence and refine biomarkers in human trials.
See the Products Available:
Healthy Leukopaks
Through Sanguine's direct-to-patient approach, they can identify healthy donors from their 70k donor network and perform leukapheresis to provide enriched Research Use Only (RUO) apheresis products collected from the same donor. This provides a reliable and consistent source of up to 10 billion immune cells, including peripheral blood mononuclear cells (PBMCs) and rare CD34+ cells for biomarker, immunology, autologous and allogeneic cell therapy research and product development.
Disease State Leukopaks
Sanguine Biosciences' are also able to provide leukopaks from diseased state donors, which have been collected under IRB protocols.
Sanguine has over 30 conditions approved for apheresis collection from their donor network of over 70K people. They have access to donors suffering from the following conditions.
Autoimmune Diseases:
Crohn's Disease (CD)
Ulcerative Colitis (UC)
Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Coeliac Disease
Arthritis
Asthma
Atopic Dermatitis (AD)
Chronic obstructive pulmonary disease (COPD)
Fibromyalgia
Gout
Hashimoto's Disease
Hidradenitis Suppurativa (HS)
Myasthenia Gravis
Osteoarthritis
Psoriasis
Scleroderma
Sjogren's Syndrome
Vitiligo
Metabolic & Exposure-Related
Chronic Kidney Disease (CKD)
Diabetes Mellitus Type 1
Diabetes Mellitus Type 2
Hypercholesterolemia
Hypertension
Hypothyroidism
Pulmonary Arterial Hypertension (PAH)
Chronic Obstructive Pulmonary Disease (COPD)
Infectious
HIV
Hepatitis B
Hepatitis C
Genetic
Cystic Fibrosis (CF)
Sickle Cell Trait
Features of Sanguine Leukopaks
Diverse Donor Network
- 70,000 patient donors from across the USA
- Confirmed disease diagnosis via medical records
- Medical histories
- Inclusion/exclusion criteria
- Ability to screen donors for distinct biomarker signatures
Comprehensive Donor Data
- Annotated medical records
- Study-specific questionnaires
- Infectious disease status
- HLA typing class 1 & 2
- Complete blood count
- Total nucleated cell count (TNC)
- Demographics
Quality
- Adherence to standards and protocols ensures high cell viability and recovery
- Certificate of analysis
- Up to 10 billion (full) or 5 billion (half) TNCs per leukopak
Recallable Donors
- Longitudinal studies with multiple time points
- Network of qualified apheresis clinics across the USA
LeukoLots™
A leukopak provides billions of immune cells from a single donor, reducing variability and increasing reproducibility.
The challenge, however, remains that no two donations are the same and thus screening may be necessary to ensure that the donor's cells are suitable for your research.
A LeukoLot™ is a batch of PBMCs isolated from a single donor that are aliquoted and then cryopreserved. You can screen multiple LeukoLots to identify the PBMC composition that best suits your needs before committing to a whole or half leukopak.